Getting Clinical Trial Design Right the First Time with Pentara Corporation's Suzanne Hendrix, Ph.D.
We love to hear from our listeners. Send us a message. Episode 142 of Cell & Gene: The Podcast features Host Erin Harris' conversation with Pentara Corporation's CEO and Founder, Suzanne Hendrix, Ph.D., about how statistical planning can shape clinical development and the path to FDA approval. Dr. Hendrix shares practical guidance for CGT developers on selecting meaningful endpoints, determining sample size, using natural history data, and considering alternative trial designs for small patient populations. She also explains why CDISC data standards, early statistical analysis plans, and alignment with the FDA are critical to avoiding costly trial redesigns, regulatory questions, and delays. Subscribe to the podcast! Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn